Elacytarabine - scientific publications and posters


Scientific publications

  1. Rizzieri D, Vey R, Thomas X, et al. A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline.
    Abstract #46. ASH 2012. Oral presentation 9 Dec 2012 by Dr. D. Rizzieri.
  2. Adema AD, Smid K, Loosekot N, et al. Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126, Invest New Drugs, 2012;30(5):1908-1916. Epub 2011 Oct 15.
  3. O’Brien S, Rizzieri D, Vey N, et al., Elacytarabine has single-agent activity in patients with advanced acute myeloid leukaemia, Br J Haematol, 2012;158(5):581-8. Epub 2012 Jun 15.
  4. Giles FJ, Vey N, Rizzieri D, et al., Phase I and pharmacokinetic study of elacytarabine, a novel 5’-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies, Leukemia, 2012;26(7):1686-9. Epub 2012 Jan 6.
  5. Giles FJ, Rizzieri D, Ravandi F, et al., Elacytarabine, a novel 5'-elaidic acid derivative of cytarabine, and idarubicin combination is active in refractory acute myeloid leukemia, Leuk Res., 2012;36(4):e71-73. Epub 2012 Jan 9.
  6. Vey N, Elacytarabine – A New Agent in the Treatment of Relapsed/Refractory Acute Myeloid Leukaemia, European Oncology & Haematology, 2012;8(2):111–115.
  7. Pignata, S, Amant F,  Scambia G et al., A Phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy, Cancer Chemother Pharmacol, 2011;68:1347–1353.
  8. Burke AC & Giles FJ, Elacytarabine - lipid vector technology overcoming drug resistance in acute myeloid leukemia, Expert Opin Investig Drugs, 2011;20(12):1707-1715. Epub 2011 Nov 1.
  9. Galmarini CM, Myhren F, Sandvold ML, CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines, Br J Haematology, 2009;144(2):273-275. Epub 2008 Nov 19.

Scientific posters (PDFs)

  1. Seng Yue C, Gandhi V, O'Brien S et al. Novel Population Pharmacokinetic Modeling of Arabinosyl Cytosine Triphosphate: Insights on potential preferential formation of Ara-CTP directly from Elacytarabine as well as from Ara-C, American Society of Hematology (ASH), 2012; Abstract #3547.
  2. Murray MP, Hagen S, Hals P-A et al., Initial characterization of the toxicity and efficacy of elacytarabine (CP-4055), a novel antileukemic agent, using a multidimensional exposure-response relationship model, American Society of Clinical Oncology (ASCO), 2012; Abstract #6619.
  3. Knapper S, Smith M, Chevassut T et al., The Pharmacokinetics of Elacytarabine in AML, European Hematology Association (EHA) 2012; Abstract #990.
  4. Rizzieri D, Vey N, Schlenk RF et al., A Phase II study of elacytarabine / idarubicin as second-course remission-induction therapy in patients with AML (CP4055-205), American Society of Hematology (ASH) 2011; Abstract #42825.
  5. Rizzieri D, Vey N, Gobbi M et al., CLAVELA, a Randomised Phase III Study of Elacytarabine (CP-4055) vs. Investigator's Choice in Patients with Late Stage Acute Myeloid leukemia (AML). American Society of Clinical Oncology (ASCO) 2011; Abstract #83258.
  6. Rizzieri D, Krug U, Sclenk RF et al., A Phase II Study of Elacytarabine (CP-4055) plus Idarubicin as Second Course Remission-Induction Therapy in Patients with Acute Myeloid Leukaemia. American Society of Clinical Oncology (ASCO) 2011; Abstract #83277.
  7. Adema AD, Smid K, Loosekot N et al., Fatty acid derivatives of cytarabine and gemcitabine, CP-4055 and CP-4126, show prolonged cellular retention compared to the parent drug. American Association for Cancer Research (AACR) 2008; Abstract #5740.